
Lenvatinib/Pembrolizumab Yields 40-Month OS in Pretreated Thymic Tumors
Key Takeaways
- In PECATI (n=43; 84% thymic carcinoma), heavily pretreated, stage IVB–predominant disease still achieved prolonged PFS and OS versus historical second-line expectations.
- Response activity was modest (25.6% ORR) yet durable, with median duration of response unreached and a 53.0% 36-month overall survival rate.
Final PECATI results show a median PFS of 22.1 months and median OS of 40.2 months with lenvatinib plus pembrolizumab in pretreated B3 thymoma and thymic carcinoma.
The combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) led to durable disease control and a median overall survival (OS) of more than 3 years in patients with advanced B3 thymoma (B3-T) or thymic carcinoma (TC) that progressed after platinum-based chemotherapy, according to the final analysis of a phase 2 study published in the Journal of Thoracic Oncology.1
Among 43 patients in the single-arm PECATI trial (NCT04710628), median progression-free survival (PFS) was 22.1 months (95% CI, 10.9-25.1) and median OS was 40.2 months (95% CI, 19.1-not estimated), with 24.6 months of median follow-up. The 36-month OS rate was 53.0%, and the confirmed objective response rate (ORR) was 25.6%, with the median duration of response not reached.
“The final results of the PECATI trial support the combination of lenvatinib plus pembrolizumab as a potential treatment option in pretreated advanced B3-T and TC,” wrote Jordi Remon, MD, PhD, of the Department of Cancer Medicine at Gustave Roussy in Villejuif, France, and his coauthors, in the study.
Study Design
PECATI enrolled patients with metastatic B3-T or TC whose disease had progressed on at least 1 platinum-based chemotherapy regimen; those with autoimmune disorders were excluded. Patients received lenvatinib 20 mg orally once daily and pembrolizumab 200 mg intravenously every 3 weeks, continuing for up to 35 cycles until disease progression or unacceptable toxicity.
The trial
Of the 43 patients enrolled, the median age was 57 years (range, 33-81), and 84% had thymic carcinoma. Masaoka-Koga stage IVB disease was present in 65%, 51.2% had 3 or more metastatic sites, and 44.2% had received 2 or more prior lines of therapy for advanced disease.
Safety Findings
Although the investigators characterized the safety profile as manageable, they cautioned that close monitoring is needed. Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 44.2% of patients.Treatment-related toxicity led 27.9% of patients to discontinue at least 1 of the study drugs.1,2 Immune-related adverse events (AEs) occurred in 39.5% of patients, and serious events included colitis, pneumonitis, myocarditis, encephalitis, and hepatotoxicity; the rate of grade 3 immune-related AEs was 11.6%.1,2 Two patients (4.7%) died of grade 5 events that investigators deemed unrelated to treatment.1
Clinical Context and Limitations
No standard second-line treatment exists for advanced B3-T or TC after platinum-based chemotherapy, the authors noted.1 According to Remon in a news release from the International Association for the Study of Lung Cancer, the results suggest the combination may be an option for selected patients after platinum-based therapy, provided patients are monitored for treatment-related toxicity.2
A phase 2 investigator-initiated trial (Artemis; NCT05832827) sponsored by the National Cancer Center in Japan is investigating the combination of carboplatin/paclitaxel and lenvatinib/pembrolizumab as first-line therapy for advanced or recurrent thymic carcinomas.3
Remon also cautioned that the small sample and single-arm design do not allow the combination to be shown superior to other treatments or the contribution of each drug to be separated. He said that further prospective studies are needed to define optimal treatment sequencing, identify the patients most likely to benefit, and determine whether such combinations can improve outcomes with acceptable safety.2
REFERENCES
1. Remon J, Bironzo P, Girard N, et al. Final analysis from PECATI phase 2 trial: lenvatinib in combination with pembrolizumab in pretreated advanced B3 thymoma and thymic carcinoma. J Thorac Oncol. Published online November 13, 2026. doi:10.1016/j.jtho.2026.106154
2. Final PECATI trial results show promising long-term survival with lenvatinib plus pembrolizumab in advanced thymic tumors. News release. International Association for the Study of Lung Cancer. November 13, 2026. Accessed November 17, 2026. https://tinyurl.com/4s4pxj25
3. Okuma Y, Nomura S, Sakakibara-Konishi J, et al. Artemis: A multicenter, open-label, single-arm, phase ii study to evaluate the efficacy and safety of first-line carboplatin/paclitaxel/lenvatinib/pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas. Clin Lung Cancer. 2024;25(4):389-394. doi:10.1016/j.cllc.2024.02.002
Related to this article







